CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Dabigatran etexilate

Last Updated: July 8, 2008
Result type: Reports
Project Number: SR0140-000
Product Line: Reimbursement Review

Generic Name: Dabigatran etexilate

Brand Name: Pradaxa

Manufacturer: Boehringer Ingelheim (Canada) Ltd.

Therapeutic Area: Thromboembolism (venous), prevention

Indications: Thromboembolism (venous), prevention

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: January 28, 2009

Recommendation Type: Do not list